PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Avanafil - Erectile dysfunction
PAD Profile : Avanafil - Erectile dysfunction
Keywords :
ED, impotence, phosphodiesterase type 5 inhibitors, PDE5 inhibitors, PDE-5
Brand Names Include :
Spedra
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
05 September 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN have agreed an updated erectile dysfunction treatment pathway and associated policy statement. Please see below for further information. There is no place in therapy recommended for avanafil and this drug will be considered BLACK on the traffic light system.
Combination treatments (oral & non oral)
These treatments should not be used in combination with other treatments for erectile dysfunction due to the limited evidence available to support their use. See here for further information https://surreyccg.res-systems.net/pad/Search/DrugConditionProfile/6166
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.05. Drugs for erectile dysfunction